View details of this raise on Seedstage

Austin, TX

Developing an AI-powered platform to improve medication adherence for Alzheimer’s patients.

• AI-Powered Platform: RXSmart.ai uses AI algorithms to adapt to individual memory impairment patterns for personalized medication management.
• Strategic Partnerships: Collaborating with the University of Maryland School of Medicine for platform development and validation.
• Market Opportunity: Addressing a $9.41B market with a focus on Alzheimer’s and dementia care.
• Caregiver Support: Provides real-time alerts and peace of mind for families managing loved ones’ medications.
• Scalable Solution: Aims to improve medication adherence for 125 million Americans with chronic diseases and cognitive decline.

Bionectech is developing RXSmart.ai, an AI-powered medication adherence platform tailored for elderly patients with Alzheimer’s, dementia, and chronic diseases. The platform aims to address the significant issue of medication non-adherence, which contributes to substantial healthcare costs and preventable deaths annually. RXSmart.ai incorporates AI algorithms that adapt to individual memory impairment patterns, providing personalized care and support for patients and caregivers. The platform is currently expanding pilot testing for commercial deployment, in collaboration with the University of Maryland School of Medicine.

The medication adherence technology market is projected to grow significantly, driven by the increasing focus on Alzheimer’s and dementia care. Bionectech’s strategic partnerships and innovative technology position it to address the needs of a vulnerable population, offering a scalable solution to improve medication management and patient outcomes. The company’s approach includes simplified patient interfaces and caregiver support systems, designed to preserve patient dignity while preventing medical emergencies. Bionectech’s efforts are part of a broader initiative to tackle the intersection of medication adherence challenges and the growing Alzheimer’s epidemic.

Company Info

Bionectech is developing RXSmart.ai, an AI-powered platform to improve medication adherence for patients with Alzheimer’s and chronic diseases.

Bionectech is developing RXSmart.ai, an AI-powered platform aimed at improving medication adherence for elderly patients with Alzheimer’s, dementia, and chronic diseases. The platform is designed to address the challenges faced by memory-impaired patients, offering specialized caregiver support systems and simplified patient interfaces. By utilizing AI algorithms that adapt to individual memory impairment patterns, RXSmart.ai aims to provide gentle, memory-friendly medication reminders that help maintain patient dignity and improve adherence rates.

The platform is currently undergoing pilot testing in collaboration with the University of Maryland School of Medicine. Bionectech’s approach targets a significant healthcare issue, as medication non-adherence contributes to substantial avoidable healthcare costs and preventable deaths annually. With a focus on Alzheimer’s and dementia care, RXSmart.ai seeks to support families and caregivers by reducing the emotional and economic burdens associated with managing chronic diseases and cognitive decline.